Sex differences in distribution, management and outcomes of combined ischemic-bleeding risk following acute coronary syndrome.

Int J Cardiol

Keele Cardiovascular Research Group, Institutes of Applied Clinical Science and Primary Care and Health Sciences, Keele University, Stoke-on-Trent, United Kingdom; Department of Cardiology, Royal Stoke Hospital, University Hospital North Midlands, Stoke-on-Trent, United Kingdom.

Published: April 2021

AI Article Synopsis

  • The study analyzed ACS hospitalizations in the UK from 2010-2017, focusing on sex-based differences in management and outcomes based on bleeding-ischemic risk.
  • Both male and female patients in the dual high-risk group were significantly less likely to receive guideline-recommended therapies, leading to worse health outcomes.
  • Females exhibited more pronounced disparities, facing higher rates of adverse events and mortality compared to males, highlighting the need for improved treatment strategies, particularly for women at high risk.

Article Abstract

Background: Risk factors for further bleeding and ischemic events after acute coronary syndrome (ACS) often overlap. Little is known about sex-based differences in the management and outcomes of ACS patients according to their combined bleeding-ischemic risk.

Methods: All ACS hospitalizations in the United Kingdom (2010-2017) were retrospectively analyzed, stratified by sex and bleeding-ischemic risk combination (using CRUSADE and GRACE scores). Multivariable logistic regression was performed to examine association between risk-groups and 1) receipt of guideline-recommended management and 2) in-hospital outcomes.

Results: Of 584,360 patients, a third of males (32.3%) and females (32.6%) were in the dual high-risk group (High CRUSADE- High GRACE). In comparison to the dual low-risk group (Low CRUSADE-Low GRACE), the dual high-risk patients of both sexes were 59-83% less likely to receive inpatient revascularisation (PCI or CABG) and 50% less likely to receive dual antiplatelet therapy (DAPT) on discharge, with a significant increase in odds of MACE (~8 to 9-fold), all-cause and cardiac mortality (25 to 35-fold), and bleeding (78-91%). The greatest difference in management and clinical outcomes between sexes was found in the dual-high risk group where females were less likely to receive guideline-recommended therapy (revascularisation and DAPT), compared to males, and were more likely to experience MACE, all-cause and cardiac mortality.

Conclusion: ACS patients with dual high-risk for bleeding and recurrent ischemia, especially females, are less likely to receive guideline-recommended therapy and experience significantly worse outcomes. Novel strategies are needed to effectively manage this highly prevalent, complex patient group and address the under-treatment of females.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijcard.2020.12.063DOI Listing

Publication Analysis

Top Keywords

dual high-risk
12
management outcomes
8
acute coronary
8
coronary syndrome
8
acs patients
8
all-cause cardiac
8
females receive
8
receive guideline-recommended
8
guideline-recommended therapy
8
dual
5

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!